Mazdutide, also known as IBI362, is a long-acting synthetic oxyntomodulin analog and pioneering dual receptor agonist targeting both GLP?1 receptor and glucagon (GCG) receptor. Distinct from single-target GLP-1 peptides, this molecule is engineered with fatty acid side chain modification to bind to serum albumin, greatly extending its in-vivo half-life and supporting once-weekly dosing in research protocols.

The dual-receptor activation brings two sets of complementary biological effects. Activation of GLP?1 receptor stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying and enhances satiety signals. Meanwhile, glucagon receptor activation elevates energy expenditure and promotes hepatic lipid metabolism. This unique dual mechanism makes it widely studied for research on type 2 diabetes, obesity, non-alcoholic steatohepatitis (NASH) and other cardiometabolic related research models.

Our Mazdutide is manufactured via solid-phase peptide synthesis, followed by rigorous purification and lyophilization. Every batch is accompanied by full COA report including HPLC purity, MS mass identification, water content and residual solvent test. The lyophilized powder form minimizes degradation during transportation and long-term storage, which is convenient for laboratory reconstitution and formulation development.

This peptide is favored by research institutions and pharmaceutical R&D teams for exploring metabolic regulation, glucose homeostasis, fat metabolism and related preclinical studies. We maintain strict quality control throughout synthesis, purification, lyophilization and packaging process to guarantee batch-to-batch consistency. We can provide flexible packaging specifications according to customers’ laboratory research requirements.